Global Oropharyngeal Candidiasis Market Size and Trends
Global oropharyngeal candidiasis market was valued at US$ 456 Mn in 2023 and is expected to reach US$ 630.4 Mn by 2031, exhibiting at a compound annual growth rate (CAGR) of 4.1% from 2024 to 2031.
Global Oropharyngeal Candidiasis Market- Trends
- Increasing online purchase of drugs: The trend of purchasing drugs online has been steadily growing over the past few years. With rising online drug purchases, companies operating in this market are recognizing the need to enhance their direct-to-consumer strategies. Many are ramping up their own online sales channels or partnering with major pharmacies and websites to ensure their antifungal drug products can be easily obtained by patients searching virtually. This allows them to capture a portion of the expanding e-pharmacy demand and stay relevant as digital transformation of the healthcare industry progresses. At the same time, distribution is broadening beyond traditional pharmacy counters to internet platforms, mobile apps, and subscription
- Advent of combination therapies: The trend of combination therapies is significantly impacting the global oropharyngeal candidiasis market in positive ways. By combining drugs that have different mechanisms of action against Candida infections, combination regimens allow for synergistic anti-fungal activity. This helps to overcome resistance issues and provides broader spectrum of activity against various Candida species. Combination drugs for oropharyngeal candidiasis are more effective at treating both azole-susceptible and resistant Candida strains as compared to monotherapy. They also help to reduce the risk of developing resistance during the course of treatment. This improves clinical cure and relapse rates for patients. With combination regimens becoming the preferred approach for managing severe and recurrent Candida infections, drug manufacturers are increasingly focusing on developing fixed-dose combination drug formulations.
U.S.: 
U.K. : 
India : 